tradingkey.logo
tradingkey.logo
Pesquisar

Eton Pharmaceuticals Inc

ETON
Adicionar à lista de desejos
37.500USD
+0.870+2.38%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
1.03BValor de mercado
PerdaP/L TTM

Mais detalhes de Eton Pharmaceuticals Inc Empresa

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Informações de Eton Pharmaceuticals Inc

Código da empresaETON
Nome da EmpresaEton Pharmaceuticals Inc
Data de listagemNov 09, 2018
CEOBrynjelsen (Sean E)
Número de funcionários31
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 09
Endereço21925 W Field Pkwy Ste 235
CidadeDEER PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60010-7278
Telefone18477877361
Sitehttps://etonpharma.com/
Código da empresaETON
Data de listagemNov 09, 2018
CEOBrynjelsen (Sean E)

Executivos da empresa Eton Pharmaceuticals Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

Perguntas frequentes

Quem são os cinco principais acionistas de Eton Pharmaceuticals Inc?

Os cinco principais acionistas de Eton Pharmaceuticals Inc são: Mr. Sean E. Brynjelsen

Quantas instituições possuem ações da Eton Pharmaceuticals Inc (ETON)?

Em 2026Q1, 235 instituições possuíam ações da Eton Pharmaceuticals Inc, com valor de mercado aproximado de 15.99M, representando 58.43% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3678435.00.